Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arcadia BiosciencesRKDA +3.33%42 Earnings per Share (Diluted) is $-4.56 as of Jun. 2026. GuruFocus rates RKDA with a GF Score™ of 42/100 and a GF Value™ of $2.15 (Possible Value Trap). The stock has 4 warning signs investors should review. Among 1,525 Consumer Packaged Goods companies, Arcadia Biosciences ranks better than 82.75% on this metric.
Arcadia Biosciences's EPS (Basic) for the
three
months ended in Jun. 2026 was $-2.09.
Its EPS (Basic) for the trailing twelve months (TTM) ended in Jun. 2026 was $-4.55.
During the past 3 years, the average EPS without NRIGrowth Rate was 42.90% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 45.90% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was 41.90% per year.
During the past 13 years, Arcadia Biosciences's highest 3-Year average EPS without NRI Growth Rate was 61.00% per year. The lowest was -24.20% per year. And the median was 35.10% per year.
Arcadia Biosciences (NAS:RKDA) Earnings per Share (Diluted) Explanation
Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Arcadia Biosciences Earnings per Share (Diluted) Related Terms
Arcadia Biosciences Earnings per Share (Diluted) Historical Data
* Premium members only.
The historical data trend for Arcadia Biosciences's Earnings per Share (Diluted) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Arcadia Biosciences Earnings per Share (Diluted) Chart
RKDA vs HIGR, SNBH, ARRT: Earnings per Share (Diluted) Comparison
For the Packaged Foods subindustry, Arcadia Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arcadia Biosciences PE Ratio vs Consumer Packaged Goods Industry
For the Consumer Packaged Goods industry and Consumer Defensive sector, Arcadia Biosciences's PE Ratio distribution charts can be found below:
* The bar in red indicates where Arcadia Biosciences's PE Ratio falls into.
Arcadia Biosciences Earnings per Share (Diluted) Calculation
Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.
Arcadia Biosciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2025 is calculated as
Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-4.56
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.
What does a Earnings per Share (Diluted) of $-4.56 mean?
Arcadia Biosciences (RKDA) has a Earnings per Share (Diluted) of $-4.56 as of Jun. 2026. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Arcadia Biosciences and its competitors. According to the industry distribution chart, Arcadia Biosciences ranks #263 out of 1525 companies in the Consumer Packaged Goods industry, placing it in the top 17.2%.
Is Arcadia Biosciences' Earnings per Share (Diluted) too high?
Arcadia Biosciences' current Earnings per Share (Diluted) is $-4.56. Based on the distribution chart, Arcadia Biosciences ranks #263 out of 1525 companies in the Consumer Packaged Goods industry, which is in the top quartile — a strong position relative to peers. Overall, Arcadia Biosciences has a GF Score™ of 42/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arcadia Biosciences' Earnings per Share (Diluted) compare to HIGR and SNBH?
According to the Consumer Packaged Goods industry distribution chart, Arcadia Biosciences ranks #263 out of 1525 companies for Earnings per Share (Diluted). This places Arcadia Biosciences in the top 17% of its industry — outperforming the majority of peers. The industry median Earnings per Share (Diluted) is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Earnings per Share (Diluted) for a Consumer Packaged Goods company?
The median Earnings per Share (Diluted) among Consumer Packaged Goods companies is 7.30, based on 1,525 companies in the industry. Companies in the top quartile (top 25%) have a Earnings per Share (Diluted) significantly above this median, while those in the bottom quartile fall well below. However, Earnings per Share (Diluted) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Earnings per Share (Diluted) mean?
A high Earnings per Share (Diluted) can signal that a stock is expensive relative to its fundamentals. Diluted EPS equals net earnings divided by average shares outstanding, including dilutive securities. View historical data on Arcadia Biosciences and its competitors. For the Consumer Packaged Goods industry, the median Earnings per Share (Diluted) is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arcadia Biosciences's current Earnings per Share (Diluted) is $-4.56. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcadia Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcadia Biosciences (RKDA) is currently considered Possible Value Trap. The stock's GF Value™ is $2.15, compared to a current price of $0.53 — trading 75.5% below its estimated fair value. The current Earnings per Share (Diluted) is $-4.56. Arcadia Biosciences' overall GF Score™ is 42/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Earnings per Share (Diluted) calculated?
Earnings per Share (Diluted) is calculated from a company's financial statements. For Arcadia Biosciences (RKDA), the current Earnings per Share (Diluted) is $-4.56 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arcadia Biosciences (RKDA) Overvalued in 2026?
Based on GuruFocus' analysis, Arcadia Biosciences stock appears to be undervalued.
The current stock price of $0.53 is trading 75.5% below its estimated GF Value™ of $2.15.
GuruFocus considers Arcadia Biosciences to be Possible Value Trap.
Key valuation signals for RKDA:
Earnings per Share (Diluted): $-4.56
GF Value™: $2.15 vs. price of $0.53 (75.5% below fair value)
No single metric tells the full story. See the RKDA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arcadia Biosciences Inc is a company with science-based approaches to develop high value products and drive innovation in the consumer goods industry. The company has one operating and reportable segment, which derives revenue from the sale of Zola coconut water. The company's consumer brands in the food, beverage, and body care categories, and others. Its products include: Zola Coconut Water, and Agronomic Wheat Traits. Geographically, the company operates in United States, Argentina, India, and Canada. It derives maximum revenue from United States.
42GF Score
Get the complete analysis for RKDA
Earnings per Share (Diluted) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
RKDA has been successfully added to your 
